Navigation Links
Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
Date:7/10/2008

Provides Update on Carfilzomib Development Program in Multiple Myeloma

SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Proteolix, Inc. today announced that patient dosing has commenced in a Phase 1b clinical trial to evaluate the safety and efficacy of Proteolix's lead anti-cancer agent, carfilzomib (PR-171), in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma. Carfilzomib selectively blocks proteasome activity, causing apoptosis in cancer cells. In single agent Phase 1 studies carfilzomib has demonstrated encouraging anti-tumor activity and has been generally well tolerated.

The Phase 1b clinical trial is designed to evaluate safety and to establish a maximum-tolerated dose of carfilzomib in combination with lenalidomide and dexamethasone on a twenty-eight day treatment cycle. Lenalidomide in combination with dexamethasone is indicated for use in patients with multiple myeloma who have had at least one prior therapy. Patients will be divided into four cohorts and will receive escalating doses of carfilzomib and lenalidomide, combined with a set dose of dexamethasone. A secondary endpoint for the trial is overall response rate at four months.

"Carfilzomib has been generally well-tolerated in patients and we believe that the product's selectivity and potency provide a solid rationale for use in combination with existing treatment protocols," said Lori Kunkel, M.D., Proteolix's Chief Medical Officer. "Initiating our first combination trial of carfilzomib complements our multi-pronged strategy to thoroughly explore carfilzomib's potential in the treatment of patients with multiple myeloma for whom treatment options may be limited."

Carfilzomib Clinical Program in Multiple Myeloma

In addition to the Phase 1b clinical trial announced today, Proteolix is currently evaluating carfilzomib as a single agent for the treatment of multiple myeloma in two Phase 2 clinical trials.

A Pha
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 According ... Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental Lasers), Current Trends, ... MarketsandMarkets, the global Dental Equipment Market is expected to ... in 2014, growing at a CAGR of 5.7% ... market data tables and 61 figures spread through ...
(Date:8/27/2014)... , Aug. 27, 2014 ISPE ... that it has released a preview of its ... pharmaceutical industry avoid drug shortages and maintain a robust ... The Plan, a first for the industry, ... biopharmaceutical industry members and describes how industry can best ...
(Date:8/27/2014)... New York , August 27, 2014 ... United States  Laparoscopes Market Outlook to ... 2020", provides key market data on the United ... millions of US dollars, volume (in units) and average ... (Rigid Tip Video Laparoscopes and Flexible Tip Video Laparoscopes), ...
Breaking Medicine Technology:Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3ISPE Releases First Look at its Plan to Prevent Drug Shortages 2ISPE Releases First Look at its Plan to Prevent Drug Shortages 3ISPE Releases First Look at its Plan to Prevent Drug Shortages 4United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 2United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 3United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 4United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 5
... 11, 2011 Rapid Fire Marketing (Pink ... wholly owned subsidiary, Medical Cannabis Management (MCM), ... cultivation and growing of medical cannabis. Management of MCM ... will significantly increase revenue and earnings through 2011 and ...
... April 11, 2011 ConvaTec, a world-leading developer ... and hospital care, today announced that Holy Family ... which offers a line of products designed to ... therapy (NPWT). ConvaTec Negative Pressure features the Engenex ...
Cached Medicine Technology:Rapid Fire Marketing: Medical Cannabis Management Cleared for Medical Cannabis Cultivation 2Holy Family Medical Center Selects ConvaTec Negative Pressure for Wound Care 2Holy Family Medical Center Selects ConvaTec Negative Pressure for Wound Care 3
(Date:8/27/2014)... 27, 2014 Will Holbrook, CP LP, ... Will has over 15 years of experience in the ... Rome, Georgia with a Bachelor of Science degree with ... He received his graduate degree in prosthetics at ... to have Will join us at Fourroux,” says Keith ...
(Date:8/27/2014)... (HealthDay News) -- In a new study done from ... your blood pressure steadily increases if you ascend to ... widely used to treat high blood pressure was ineffective ... findings, reported online Aug. 27 in the European ... but those at sea level who have sleep apnea, ...
(Date:8/27/2014)... BESLER Consulting , a leading provider of ... pleased to announce that it has been named to ... The list represents the most comprehensive look at an ... "It's been an exciting year for our company and ... Inc. 5000 list,” said Jonathan Besler, BESLER’s President and ...
(Date:8/27/2014)... IL (PRWEB) August 27, 2014 The ... announce the recipients of the 2014-2016 Basic Research Fellowships ... early career scientists, the ABTA is seeding the field ... to change our understanding of the causes, effects, diagnosis ... selected by a scientific committee based on the potential ...
(Date:8/27/2014)... 2014) An experimental drug designed to help regulate the ... for anemia of inflammation, according to results from the first ... in Blood , the Journal of the ... condition that occurs when red blood cells are in short ... anemia, the body does not get enough oxygen, since there ...
Breaking Medicine News(10 mins):Health News:Everest Study Finds High Altitude Affects Blood Pressure 2Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Drug represents first potential treatment for common anemia 2
... On May 30, 2008, CareToLive will,take to the ... Madison, Atlanta, Seattle, Dearborn, and Tampa.,Joining us will be ... Live, and the Sarcoma Foundation of America. We are ... protest., 1 in 6 men get prostate cancer. ...
... MED3OOO Group, Inc. (MED3OOO), a,national healthcare management and ... subsidiary of MED3OOO, for billing, marketing, and,business support ... of the South,Carolina Provider Outreach and Education (POE) ... select members that represent key groups,from the provider,s ...
... Bill Gives FDA Regulatory Authority Over Tobacco, ... organization in the country, today announces their,support of ... Control,Act." The legislation gives FDA regulatory authority over ... this important legislation this year.,H.R. 1108 has broad ...
... Research Council (BBSRC) have found a fast and effective way ... the University of Oxford and The Open University, Dr Lynne ... fruit flies that means flies can now be used to ... work published today in the journal Aging Cell, the researchers ...
... The situation for children,continues to worsen in Myanmar ... many more are living in desperate conditions in relief,camps, ... dead bodies, a,UNICEF report stated today., The information ... 10 offices in Myanmar. It details the most urgent ...
... surgery, , , SUNDAY, May 11 (HealthDay News) -- Human spines ... twist, reach and more. , But, in some people, the ... spine takes on an "S" or "C" shape. , This ... million Americans, according to the National Scoliosis Foundation. While it ...
Cached Medicine News:Health News:FDA Says, 'Wait' To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Immunotherapy 2Health News:FDA Says, 'Wait' To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Immunotherapy 3Health News:PSA, LLC, a MED3OOO Company, Selected as a Member of the SC Provider Outreach and Education Advisory Group 2Health News:PSA, LLC, a MED3OOO Company, Selected as a Member of the SC Provider Outreach and Education Advisory Group 3Health News:Human aging gene found in flies 2Health News:UNICEF REPORT: Desperate Conditions for Children in Camps Without Clean Water as Cyclone Aftermath Worsens 2Health News:UNICEF REPORT: Desperate Conditions for Children in Camps Without Clean Water as Cyclone Aftermath Worsens 3Health News:UNICEF REPORT: Desperate Conditions for Children in Camps Without Clean Water as Cyclone Aftermath Worsens 4Health News:Scoliosis: An Unnatural Curve 2Health News:Scoliosis: An Unnatural Curve 3
IDS Rapid NF Plus, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Bax detection system is a fast and accurate test for screening food and environmental samples by breaking them down to genetic level, using the power of the polymerase chain reaction (PCR) to detect ...
A versatile plate washer and/or dispenser that aspirates from the top down without immersing the aspirating tubes in the well, ensuring overflow protection. 5 programmable protocols....
Medicine Products: